Multiple Myeloma
Conditions
Keywords
Multiple Myeloma, FcRL5
Brief summary
This is an open label, single-arm, Phase 2 study to evaluate the efficacy and safety of Anti-FcRL5 CAR-T in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture. Anti-FcRL5 chimeric antigen receptor (CAR) modified T cells. Prior to Anti-FcRL5 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide.
Detailed description
This open label, single-arm, Phase 2 study aims to evaluate the efficacy and safety of Anti-FcRL5 CAR-T in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture. Anti-FcRL5 chimeric antigen receptor (CAR) modified T cells. Prior to Anti-FcRL5 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide. After infusion, the investigators will observe the characteristics of dose limited toxicity (DLT), and determine the maximum tolerable agent MTD and rp2d were confirmed. To provide basis for the dosage and treatment plan of cell products in follow-up clinical trials.
Interventions
DRUGanti-FcRL5 CAR-T
anti-FcRL5 autologous CAR T cells will be infused at a dose ranging from 1 - 2 x 10\^6/kg CAR+ T cells after receiving lymphodepleting chemotherapy.
Sponsors
Xuzhou Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
The set subject inclusion criteria include multiple documents of multiple myeloma, no effective treatment options (e. g. autologous or allogeneic stem cell transplantation) and limited outcome (\<2 years) with existing therapies, as follows: 1. Age is 18\ 70 years old; 2. Expected survival period of\>12 weeks; 3. Multiple myeloma was diagnosed by physical examination, pathological examination, laboratory examination and imaging; 4. Patients with refractory multiple myeloma; 5. Patients with multiple myeloma recurrence; 6. ALT and AST \<3 times normal; bilirubin \<2.0mg / dl; 7. Quality of survival score (KPS)\> 50%; 8. The patient has no serious heart, liver, kidney and other diseases; 9. Recurrence or no disease remission after hematopoietic stem cell transplantation or cellular immunotherapy; 10. Is not suitable for stem cell transplantation conditions or to abandon transplantation due to conditional restrictions; 11. Blood can be obtained intravenously, without other contraindications to leukapheresis; 12. Understand and voluntarily sign a written informed consent form.
Exclusion criteria
1. Women who are pregnant or breastfeeding, or who have a pregnancy plan within six months; 2. Infectious diseases (such as HIV, active tuberculosis, etc.); 3. Active hepatitis B or hepatitis C infection; 4. Feasibility assessment screening demonstrated \<10% transfection of targeted lymphocytes or underamplification under CD3 / CD28 costimulation (\<5-fold); 5. Abnormal vital signs, and unable to cooperate with the examination; 6. Have mental or mental illness who cannot cooperate with the treatment and efficacy evaluation; 7. Highly allergic constitution or have a history of severe allergies, especially allergic to IL-2; 8. Subjects with a systemic infection or a severe local infection requiring anti-infective treatment; 9. Subjects with severe autoimmune disease; 10. The doctor believes there were other reasons for inclusion
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events | Baseline up to 28 days after CAR-T cells infusion | Adverse events assessed according to NCI-CTCAE v5.0 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| overall response rate (ORR) | Month 6, 12, 18 and 24 | Assessment of ORR at Month 6, 12, 18 and 24 |
| complete response (CR) | Month 6, 12, 18 and 24 | Assessment of CR at Month 6, 12, 18 and 24 |
| Overall survival (OS) | Month 6, 12, 18 and 24 | Assessment of OS at Month 6, 12, 18 and 24 |
| Event-free survival (EFS) | Month 6, 12, 18 and 24 | Assessment of EFS at Month 6, 12, 18 and 24 |
Countries
China
Contacts
Primary ContactKailin Xu, MD.,PD.
Outcome results
None listed